Haemophilus influenzae Infections Following Licensure of the Hib Vaccine

W. James Alexander, Joseph F.e. Shaw, J. Richard Holmes, Michael T. Osterholm

Research output: Contribution to journalLetterpeer-review

2 Scopus citations


To the Editor: In April 1985, the Food and Drug Administration licensed the Haemophilus influenzae type b (Hib) vaccine for use in the United States, after a field trial had confirmed its efficacy.1 This vaccine, prepared from the capsular polysaccharide of the bacterium, has been envisioned as a cost-effective agent for reducing morbidity and mortality due to H. influenzae type b disease.2 Both the Immunization Practices Advisory Committee and the American Academy of Pediatrics have recommended universal vaccination for children 24 months of age.3,4 The U.S. Public Health Service has recommended that consideration be given to vaccinating children at high…

Original languageEnglish (US)
Pages (from-to)167-168
Number of pages2
JournalNew England Journal of Medicine
Issue number3
StatePublished - Jul 16 1987


Dive into the research topics of 'Haemophilus influenzae Infections Following Licensure of the Hib Vaccine'. Together they form a unique fingerprint.

Cite this